TABLE 3.
Summary of Mean Effect Estimates From Meta-analysis for Sensitivity, Specificity, PPVadj, and NPVadj for the TSP-9 Test [mean, (95% CI)]
| Sensitivity* | Specificity* | NPVadj (TSP-9 high/int risk)* | PPVadj (TSP-9 high/int risk)* | PPVadj (TSP-9 high risk)† | |
|---|---|---|---|---|---|
| Common-effect model | 0.61 (0.54; 0.68) | 0.81 (0.78; 0.84) | 0.97 (0.96; 0.98) | 0.14 (0.09; 0.21) | 0.28 (0.17; 0.42) |
| Random-effects model | 0.62 (0.48;0.75) | 0.81 (0.77; 0.85) | 0.97 (0.96; 0.98) | 0.14 (0.09; 0.21) | 0.28 (0.17; 0.42) |
*
For the calculation of sensitivity and specificity, NPVadj, and PPVadj, TSP-9 high- and intermediate-risk (high/int) results were combined.
†
The PPVadj was also calculated using the TSP-9 high-risk result. For this analysis, the Khoshiwal et al, 202324 study was not included because the number of only high-risk results was not reported.
PPVadj indicates prevalence-adjusted positive predictive value; NPVadj, prevalence-adjusted negative predictive value; TSP-9, tissue systems pathology-9; CI, confidence interval.